Avacta Group PLC rallied on Friday after the company said it had received registration notification for its AffiDX coronavirus sidestream antigen test in the European Union.
The developer of the diagnostic system said the registration allows him to place the product on the market in all 27 EU countries for professional use.
Avacta said it already has numerous commercial discussions with distributors and end users.
The stock was up 24.5p, or 11%, at 10.15 GMT to 243.5p.
Email Matteo Castia at [email protected]